

Disclosures

Personal Commercial (4)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|---|---------------------------|--------------------|-------------------------------|
| Self | | | |
| Abbott | Consultant Fees/Honoraria | Modest (< \$5,000) | Acute Coronary Syndromes |
| Amgen | Consultant Fees/Honoraria | Modest (< \$5,000) | Stable Ischemic Heart Disease |
| AstraZeneca | Consultant Fees/Honoraria | Modest (< \$5,000) | Acute Coronary Syndromes |
| Boston Scientific Consultant Fees/Honoraria | | Modest (< \$5,000) | Stable Ischemic Heart Disease |

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (2)

| Trial Name | Trial Sponsor | Trial Funding Source |
|------------|-------------------------|----------------------|
| PROTECT IV | Abiomed | |
| SOS AMI | Idorsia Pharmaceuticals | |

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (2)

| Year | Case Title | Represented | Description | Compensation |
|------|---|-------------|--|--------------------|
| Self | | | | |
| 2022 | 2 acute MI Defendant the patient was hospitalized with MI and diagnosis was delayed resulting in delayed treatment, eventually patient developed heart failure. | | Modest (< \$5,000) | |
| 2022 | injury after PCI | Defendant | patient who underwent PCI claiming injury in the form of pain against inteventional cardiologist | Modest (< \$5,000) |

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 9/21/2023

URL for full agreement: http://disclosures. acc. org/Public/Definition/Certified Education Attest at ion Agreement agree

Confidentiality, Disclosure and Assignment Agreement | Signed on 9/21/2023

 $\textit{URL for full agreement: http://disclosures.acc.org/Public/Definition/Confidentiality Disclosure and Assignment Agreement and Assignment Agreement agreem$

Embargo | Signed on 9/21/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 9/21/2023

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.